Latest Breaking News On - Thibault boutherin - Page 1 : vimarsana.com

Evotec SE (NASDAQ:EVO) Q1 2024 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2024 Conference Call. I am Sandra, the chorus call operator.

United statesUnited kingdomEvotec biologicsFalko friedrichsJoseph heddenMario polywkaChristian ehmannMichael ryskinMatthias eversCraig johnstonPeter verdultMarcy lyonVolker braunBen jacksonThibault boutherinCharles weston

Grifols, S A (NASDAQ:GRFS) Q1 2024 Earnings Call Transcript

Daniel Segarra: Hello, everyone, and welcome to Grifols Conference Call. Today, we will be sharing a business update on our first quarter financial results.

United statesComunidad autonoma de catalunaDaniel segarraThibault boutherinGuilherme sampaioGraham parryThomas jonesJaime escribanoVictor grifolsCharles pitmanAlfredo arroyoPeter verdultThomas glanzmannRaimon grifolsAlvaro lenze juliaTom jones

Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript

Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

United statesChris schottEvernorth accredoGlen santangelo jefferiesEric hughesAmerica merrill lynchJason gerberryGlen santangeloRichard francisDavid amsellemDavid amsellem piper sandlerPiper sandlerBalaji prasadThibault boutherin morgan stanleyBalaji prasad barclaysChris schott jpmorgan

Bayer Slumps After $2 25 Billion Roundup Trial Loss

Bayer Slumps After $2 25 Billion Roundup Trial Loss
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

United statesBayer monsantoJames coneJohn mckivisonThibault boutherinBill andersonMorgan stanleyChief executive officer bill andersonPhiladelphia friday

Sanofi to buy Inhibrx for $2 2 billion in rare disease push

The acquisition is the latest in a string of small- and mid-sized deals as Sanofi looks to double down on innovative medicines and reduce its reliance on the blockbuster asthma medicine Dupixent.

France generalMark lappePaul hudsonThibault boutherinRoche holdingMorgan stanleyInhibrx incEnhanced potentialCalifornia based inhibrxWorld news